Rituximab in immunologic glomerular diseases

References

• Chinen J, Shearer WT. Advances in basic and clinical immunology in 2010. J Allergy Clin Immunol 2011; 127:336 - 341; PMID: 21281863; http://dx.doi.org/10.1016/j.jaci.2010.11.042
   PubMed Web of Science ®Google Scholar
• Lee SL, Ballow M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. J Allergy Clin Immunol 2010; 125:814 - 820; PMID: 20371395; http://dx.doi.org/10.1016/j.jaci.2010.02.025
   PubMed Web of Science ®Google Scholar
• Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:734 - 744; PMID: 19279120; http://dx.doi.org/10.2215/CJN.05231008
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit?. Clin J Am Soc Nephrol 2006; 1:738 - 748; PMID: 17699281; http://dx.doi.org/10.2215/CJN.01080905
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572 - 2581; PMID: 15201414; http://dx.doi.org/10.1056/NEJMoa032534
   PubMed Web of Science ®Google Scholar
• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse and re-treatment. Arthritis Rheum 2006; 54:2970 - 2982; PMID: 16947528; http://dx.doi.org/10.1002/art.22046
   PubMed Web of Science ®Google Scholar
• El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009; 9:2800 - 2807; PMID: 19845581; http://dx.doi.org/10.1111/j.1600-6143.2009.02851.x
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5:2363 - 2372; PMID: 21030574; http://dx.doi.org/10.2215/CJN.06720810
   PubMed Web of Science ®Google Scholar
• Stegall MD, Gloor JM. Deciphering antibody-mediated reje ction: new insights into mechanisms and treatmen. Curr Opin Organ Transplant 2010; 15:8 - 10; http://dx.doi.org/10.1097/MOT.0b013e3283342712; PMID: 19890210
   PubMed Web of Science ®Google Scholar
• Crew RJ, Ratner LE. ABO-incompatible kidney transplantation: current practice and the decade ahead. Curr Opin Organ Transplant 2010; 15:526 - 530; http://dx.doi.org/10.1097/MOT.0b013e32833bfbba; PMID: 20613520
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359 - 7368; PMID: 14576843; http://dx.doi.org/10.1038/sj.onc.1206939
   PubMed Web of Science ®Google Scholar
• Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121:1121 - 1132; PMID: 7684739; http://dx.doi.org/10.1083/jcb.121.5.1121
   PubMed Web of Science ®Google Scholar
• Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase Cgamma1 and PLC phospholipase Cgamma2. J Immunol 1993; 151:4494 - 4504; PMID: 7691952
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Blood 2002; 99:1314 - 1319; PMID: 11830481; http://dx.doi.org/10.1182/blood.V99.4.1314
   PubMed Web of Science ®Google Scholar
• Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3:85; PMID: 21632984; http://dx.doi.org/10.1126/scitranslmed.3002231
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99:1038 - 1043; PMID: 11807010; http://dx.doi.org/10.1182/blood.V99.3.1038
   PubMed Web of Science ®Google Scholar
• Treon SP, Mitisiades C, Mitisiades N, Young G, Doss D, Schlossman SF, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24:263 - 271; http://dx.doi.org/10.1097/00002371-200105000-00011
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 446; PMID: 10742152; http://dx.doi.org/10.1038/74704
   PubMed Web of Science ®Google Scholar
• Shimada M, Ishimoto T, Lee PY, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, et al. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF{kappa}B-dependent pathw. Nephrol Dial Transplant 2012; 27:81 - 89; PMID: 21617192; http://dx.doi.org/10.1093/ndt/gfr271
   PubMed Web of Science ®Google Scholar
• Dall'Aglio P, Meroni PL, Barcellini W, Brigati C, Chizzolini C, De Bartolo G, et al. Altered expression of B lymphocyte surface immunoglobulins in minimal change nephrotic syndrome and focal glomerulosclerosis. Nephron 1984; 37:224 - 228; PMID: 6611510; http://dx.doi.org/10.1159/000183253
   PubMedGoogle Scholar
• Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23:1269 - 1279; PMID: 18465150; http://dx.doi.org/10.1007/s00467-008-0814-1
   PubMed Web of Science ®Google Scholar
• Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24:1321 - 1328; PMID: 19421786; http://dx.doi.org/10.1007/s00467-009-1191-0
   PubMed Web of Science ®Google Scholar
• Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5:2207 - 2212; PMID: 20798255; http://dx.doi.org/10.2215/CJN.03470410
   PubMed Web of Science ®Google Scholar
• Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25:1109 - 1115; PMID: 20238230; http://dx.doi.org/10.1007/s00467-010-1465-6
   PubMed Web of Science ®Google Scholar
• Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:1308 - 1315; PMID: 21566104; http://dx.doi.org/10.2215/CJN.09421010
   PubMed Web of Science ®Google Scholar
• Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2012; 27:235 - 241; [Epub ahead of print] PMID: 21922213; http://dx.doi.org/10.1007/s00467-011-1997-4
   PubMed Web of Science ®Google Scholar
• Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24:1433 - 1438; PMID: 19495800; http://dx.doi.org/10.1007/s00467-009-1226-6
   PubMed Web of Science ®Google Scholar
• Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?. Kidney Int 2009; 76:487 - 491; PMID: 19494796; http://dx.doi.org/10.1038/ki.2009.204
   PubMed Web of Science ®Google Scholar
• van Husen M, Kemper MJ. New therapies in steroidsensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011; 26:881 - 892; PMID: 21229269; http://dx.doi.org/10.1007/s00467-010-1717-5
   PubMed Web of Science ®Google Scholar
• Benz K, Dötsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004; 19:794 - 797; PMID: 15071769; http://dx.doi.org/10.1007/s00467-004-1434-z
   PubMed Web of Science ®Google Scholar
• Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006; 21:1698 - 1700; PMID: 16932900; http://dx.doi.org/10.1007/s00467-006-0228-x
   PubMed Web of Science ®Google Scholar
• Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356:2751 - 2752; PMID: 17596616; http://dx.doi.org/10.1056/NEJMc063706
   PubMed Web of Science ®Google Scholar
• Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008; 23:481 - 485; PMID: 17973121; http://dx.doi.org/10.1007/s00467-007-0640-x
   PubMed Web of Science ®Google Scholar
• Suri M, Tran K, Sharma AP, Filler G, Grimmer J. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 2008; 40:807 - 810; PMID: 18491215; http://dx.doi.org/10.1007/s11255-008-9393-0
   PubMed Web of Science ®Google Scholar
• Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al. Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4:1317 - 1323; PMID: 19578004; http://dx.doi.org/10.2215/CJN.00570109
   PubMed Web of Science ®Google Scholar
• Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11 - 21; PMID: 19571279; http://dx.doi.org/10.1056/NEJMoa0810457
   PubMed Web of Science ®Google Scholar
• Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26:2526 - 2532; PMID: 21633097; http://dx.doi.org/10.1093/ndt/gfr247
   PubMed Web of Science ®Google Scholar
• Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543 - 1550; PMID: 21784898; http://dx.doi.org/10.1681/ASN.2010111125
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3:1652 - 1659; PMID: 18684896; http://dx.doi.org/10.2215/CJN.01730408
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117 - 125; PMID: 17943078; http://dx.doi.org/10.1038/sj.ki.5002628
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14:1851 - 1857; PMID: 12819245; http://dx.doi.org/10.1097/01.ASN.0000071511.35221.B3
   PubMed Web of Science ®Google Scholar
• Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4:1083 - 1088; PMID: 19478097; http://dx.doi.org/10.2215/CJN.06041108
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, et al. Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21:697 - 704; PMID: 20110379; http://dx.doi.org/10.1681/ASN.2009080861
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222 - 233; PMID: 20039413; http://dx.doi.org/10.1002/art.27233
   PubMed Web of Science ®Google Scholar
• Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008; 47:821 - 827; PMID: 18397955; http://dx.doi.org/10.1093/rheumatology/ken071
   PubMed Web of Science ®Google Scholar
• Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noël LH, et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008; 52:346 - 352; PMID: 18572292; http://dx.doi.org/10.1053/j.ajkd.2008.03.036
   PubMed Web of Science ®Google Scholar
• Moroni G, Gallelli B, Banfi G, Leoni A, Messa P. Rituximab monotherapy for remission induction of proliferative lupus nephritis flares: description of 3 cases. J Nephrol 2010; 23:357 - 361; PMID: 20383866
   PubMed Web of Science ®Google Scholar
• Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24:3717 - 3723; PMID: 19617257; http://dx.doi.org/10.1093/ndt/gfp336
   PubMed Web of Science ®Google Scholar
• Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology (Oxford) 2009; 48:892 - 898; PMID: 19478041; http://dx.doi.org/10.1093/rheumatology/kep124
   PubMed Web of Science ®Google Scholar
• Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20:709 - 716; PMID: 21478286; http://dx.doi.org/10.1177/0961203310395802
   PubMed Web of Science ®Google Scholar
• Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12:783 - 787; PMID: 14596429; http://dx.doi.org/10.1191/0961203303lu453cr
   PubMed Web of Science ®Google Scholar
• Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes and predictors of response. Ann Rheum Dis 2008; 67:330 - 334; PMID: 17827182; http://dx.doi.org/10.1136/ard.2007.079095
   PubMed Web of Science ®Google Scholar
• Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a longterm prospective study. Nephrol Dial Transplant 2009; 24:2157 - 2160; PMID: 19179411; http://dx.doi.org/10.1093/ndt/gfp002
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17:191 - 197; PMID: 17564773; http://dx.doi.org/10.1007/s10165-007-0565-z
   PubMedGoogle Scholar
• Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56:1263 - 1272; PMID: 17393458; http://dx.doi.org/10.1002/art.22505
   PubMed Web of Science ®Google Scholar
• Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26:67 - 71; PMID: 18799057
   PubMed Web of Science ®Google Scholar
• Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4:579 - 587; PMID: 19261822; http://dx.doi.org/10.2215/CJN.04030808
   PubMed Web of Science ®Google Scholar
• Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O, et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 2009; 89:305 - 309; PMID: 19308659; http://dx.doi.org/10.1007/s12185-009-0269-6
   PubMed Web of Science ®Google Scholar
• Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67:1724 - 1731; PMID: 18250115; http://dx.doi.org/10.1136/ard.2007.083162
   PubMed Web of Science ®Google Scholar
• Holden NJ, Williams JM, Morgan MD, Challa A, Gordon J, Pepper RJ, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011; 70:2229 - 2233; PMID: 21859691; http://dx.doi.org/10.1136/ard.2011.153890
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156 - 2168; PMID: 19565480; http://dx.doi.org/10.1002/art.24637
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45:1432 - 1436; PMID: 16632482; http://dx.doi.org/10.1093/rheumatology/kel098
   PubMed Web of Science ®Google Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262 - 268; PMID: 15641078; http://dx.doi.org/10.1002/art.20718
   PubMed Web of Science ®Google Scholar
• Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180 - 187; PMID: 16224107; http://dx.doi.org/10.1164/rccm.200507-1144OC
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculit. N Engl J Med 2010; 363:211 - 220; PMID: 20647198; http://dx.doi.org/10.1056/NEJMoa0909169
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N Engl J Med 2010; 363:221 - 232; PMID: 20647199; http://dx.doi.org/10.1056/NEJMoa0909905
   PubMed Web of Science ®Google Scholar
• Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394 - 1400; PMID: 20498238; http://dx.doi.org/10.2215/CJN.08821209
   PubMed Web of Science ®Google Scholar
• Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. [Epub ahead of print]. Ann Rheum Dis 2011; PMID: 22021864
   PubMed Web of Science ®Google Scholar
• Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, Griffith M, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011; 26:3280 - 3286; PMID: 21414973; http://dx.doi.org/10.1093/ndt/gfr127
   PubMed Web of Science ®Google Scholar
• Wink F, Houtman PM, Jansen TL. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol 2011; 30:293 - 300; PMID: 21053035; http://dx.doi.org/10.1007/s10067-010-1612-2
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferonalpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116:326 - 334; PMID: 20439619; http://dx.doi.org/10.1182/blood-2009-10-248518
   PubMed Web of Science ®Google Scholar
• Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43:34 - 38; PMID: 15112197; http://dx.doi.org/10.1053/j.ajkd.2003.12.057
   PubMed Web of Science ®Google Scholar
• Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11:48 - 55; PMID: 21821153; http://dx.doi.org/10.1016/j.autrev.2011.07.005
   PubMed Web of Science ®Google Scholar
• Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38:2308 - 2310; PMID: 16980074; http://dx.doi.org/10.1016/j.transproceed.2006.06.131
   PubMed Web of Science ®Google Scholar
• Kawano N, Ikeda N, Yoshida S, Sugio Y, Yamashita K, Uezono S, et al. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Int J Hematol 2010; 92:391 - 397; PMID: 20686877; http://dx.doi.org/10.1007/s12185-010-0638-1
   PubMed Web of Science ®Google Scholar
• Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011; 6:1609 - 1616; PMID: 21700823; http://dx.doi.org/10.2215/CJN.10611110
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNApositive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44:49 - 54; PMID: 21885355; http://dx.doi.org/10.1016/j.dld.2011.07.016
   PubMedGoogle Scholar
• Stamataki Z, Tilakaratne S, Adams DH, McKeating JA. Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One 2011; 6:25789; PMID: 21991396; http://dx.doi.org/10.1371/journal.pone.0025789
   PubMed Web of Science ®Google Scholar
• Sinha A, Nast CC, Hristea I, Vo AA, Jordan SC. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol 2011; 15:164 - 170; PMID: 21107633; http://dx.doi.org/10.1007/s10157-010-0377-x
   PubMed Web of Science ®Google Scholar
• Collins M, Navaneethan SD, Chung M, Sloand J, Goldman B, Appel G, et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis 2008; 52:1158 - 1162; PMID: 18823685; http://dx.doi.org/10.1053/j.ajkd.2008.07.011
   PubMed Web of Science ®Google Scholar
• Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, et al. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 2006; 77:527 - 529; PMID: 17042766; http://dx.doi.org/10.1111/j.1600-0609.2006.00758.x
   PubMed Web of Science ®Google Scholar
• Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002; 71:105 - 108; PMID: 12353309; http://dx.doi.org/10.1002/ajh.10204
   PubMed Web of Science ®Google Scholar
• Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28:385 - 391; PMID: 12367582; http://dx.doi.org/10.1006/bcmd.2002.0522
   PubMed Web of Science ®Google Scholar
• Lombardi AM, de Marinis GB, Scandellari R, Magalini F, Sansoni P, Ballerini PF, et al. Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thromb Res 2010; 126:154 - 156; PMID: 20193960; http://dx.doi.org/10.1016/j.thromres.2010.02.005
   PubMed Web of Science ®Google Scholar
• Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746 - 1753; PMID: 21636861; http://dx.doi.org/10.1182/blood-2011-03-341131
   PubMed Web of Science ®Google Scholar
• Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al. French Thrombotic Microangiopathies Reference Center; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med 2012; 40:104 - 111; PMID: 21926591; http://dx.doi.org/10.1097/CCM.0b013e31822e9d66
   PubMed Web of Science ®Google Scholar
• Klipa D, Mahmud N, Ahsan N. Antibody immunosuppressive therapy in solid organ transplant: Part II. MAbs 2010; 2:607 - 612; PMID: 20948291; http://dx.doi.org/10.4161/mabs.2.6.13586
   PubMed Web of Science ®Google Scholar
• Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996 - 1001; PMID: 15147435; http://dx.doi.org/10.1111/j.1600-6143.2004.00454.x
   PubMed Web of Science ®Google Scholar
• Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85:1745 - 1754; PMID: 18580466; http://dx.doi.org/10.1097/TP.0b013e3181726849
   PubMed Web of Science ®Google Scholar
• Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87:1325 - 1329; PMID: 19424032; http://dx.doi.org/10.1097/TP.0b013e3181a235fd
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360:2683 - 2685; PMID: 19535812; http://dx.doi.org/10.1056/NEJMc0808481
   PubMed Web of Science ®Google Scholar
• Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753 - 760; PMID: 18294345; http://dx.doi.org/10.1111/j.1600-6143.2008.02159.x
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immunoglobulin for desensitization during renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246 - 1255; PMID: 19384174
   PubMed Web of Science ®Google Scholar
• Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23:63 - 73; PMID: 19200217; http://dx.doi.org/10.1111/j.1399-0012.2008.00902.x
   PubMed Web of Science ®Google Scholar
• Mulley WR, Hudson FJ, Tait BD, Skene AM, Dowling JP, Kerr PG, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibodymediated rejection. Transplantation 2009; 87:286 - 289; PMID: 19155986; http://dx.doi.org/10.1097/TP.0b013e31819389cc
   PubMed Web of Science ®Google Scholar
• Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol 2008; 4:446 - 457; PMID: 18560395; http://dx.doi.org/10.1038/ncpneph0854
   PubMedGoogle Scholar
• Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103 - 109; PMID: 12110738; http://dx.doi.org/10.1056/NEJMoa013036
   PubMed Web of Science ®Google Scholar
• Wadei HM, Geiger XJ, Mai ML. Ahsan N. Recurrent glomerular diseases in the allograft: risk factors and management. Chronic allograft failure: natural history, pathogenesis, diagnosis and management 2008; Austin TX Landes Bioscience 200 - 221
   Google Scholar
• Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635 - 641; PMID: 10507481; http://dx.doi.org/10.1097/00007890-199909150-00007
   PubMed Web of Science ®Google Scholar
• Damodar A, Mustafa R, Bhatnagar J, Panesar M, Gundroo A, Zachariah M, et al. Use of anti-CD20 antibody in the treatment of post-transplant glomerulonephritis. Clin Transplant 2011; 25:375 - 379; PMID: 20384712; http://dx.doi.org/10.1111/j.1399-0012.2010.01245.x
   PubMed Web of Science ®Google Scholar
• Dall'Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34:1048 - 1055; PMID: 10585314; http://dx.doi.org/10.1016/S0272-6386(99)70010-7
   PubMed Web of Science ®Google Scholar
• Rodríguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 2009; 41:2406 - 2408; PMID: 19715934; http://dx.doi.org/10.1016/j.transproceed.2009.06.044
   PubMed Web of Science ®Google Scholar
• Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin and rituximab. Transplant Proc 2006; 38:2659 - 2660; PMID: 17098031; http://dx.doi.org/10.1016/j.transproceed.2006.07.034
   PubMed Web of Science ®Google Scholar
• Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232 - 1239; PMID: 19384172; http://dx.doi.org/10.1097/TP.0b013e31819f12be
   PubMed Web of Science ®Google Scholar
• Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88:417 - 420; PMID: 19667947; http://dx.doi.org/10.1097/TP.0b013e3181aed9d7
   PubMed Web of Science ®Google Scholar
• Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20:102 - 105; PMID: 17181660; http://dx.doi.org/10.1111/j.1432-2277.2006.00395.x
   PubMed Web of Science ®Google Scholar
• Sakai K, Takasu J, Nihei H, Yonekura T, Aoki Y, Kawamura T, et al. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 2010; 24:60 - 65; PMID: 20590697; http://dx.doi.org/10.1111/j.1399-0012.2010.01279.x
   PubMed Web of Science ®Google Scholar
• Kaito H, Kamei K, Kikuchi E, Ogura M, Matsuoka K, Nagata M, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin. Pediatr Nephrol 2010; 25:957 - 959; PMID: 20033219; http://dx.doi.org/10.1007/s00467-009-1410-8
   PubMed Web of Science ®Google Scholar
• Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5:790 - 797; PMID: 20185599; http://dx.doi.org/10.2215/CJN.04120609
   PubMed Web of Science ®Google Scholar
• Sathyan S, Khan FN, Ranga KV. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. Transplant Proc 2009; 41:3953 - 3955; PMID: 19917422; http://dx.doi.org/10.1016/j.transproceed.2009.03.100
   PubMed Web of Science ®Google Scholar
• Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10:89 - 98; PMID: 19656128; http://dx.doi.org/10.1111/j.1600-6143.2009.02785.x
   PubMed Web of Science ®Google Scholar
• Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14:696 - 699; PMID: 19796030; http://dx.doi.org/10.1111/j.1440-797.2009.01168.x
   PubMed Web of Science ®Google Scholar
• Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 2010; 25:1163 - 1167; PMID: 20140460; http://dx.doi.org/10.1007/s00467-010-1447-8
   PubMed Web of Science ®Google Scholar
• Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solidorgan transplant patients. Am J Transplant 2009; 9:244 - 245; PMID: 19133934; http://dx.doi.org/10.1111/j.1600-6143.2008.02499.x
   PubMed Web of Science ®Google Scholar